CA2427655C - Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization - Google Patents
Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization Download PDFInfo
- Publication number
- CA2427655C CA2427655C CA2427655A CA2427655A CA2427655C CA 2427655 C CA2427655 C CA 2427655C CA 2427655 A CA2427655 A CA 2427655A CA 2427655 A CA2427655 A CA 2427655A CA 2427655 C CA2427655 C CA 2427655C
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- agn
- agonist
- selective agonist
- ocular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
Methods and compositions for the treatment of ocular neovascularization (CNV) and macular degeneration. The invention includes combining laser treatment with administration of a neuroprotectant.
Description
USE OF APLHA ADRENERGIC RECEPTOR AGONIST TO REDUCE A
DECREASE IN NEUROSENSORY RETINAL FUNCTION FOLLOWING
LASER THERAPY FOR CHOROIDAL NEOVASCULARIZATION
Background Of The Invention Loss of visual acuity is a common problem associated with aging and with various conditions of the eye. Particularly troublesome is the development of unwanted neovascularization in the cornea, retina or choroid. Choroidal neovascularization leads to hemorrhage and fibrosis, with resultant visual loss in a number of recognized eye diseases, including macular degeneration, ocular histoplasmosis syndrome, myopia, diabetic retinopathy and inflammatory diseases.
Age-related macular degeneration (AND) is the leading cause of new blindness in the elderly, and choroidal neovascularization is responsible for 800 of the severe visual loss in patients with this disease.
Although the natural history of the disease is eventual quiescence and regression of the neovascularization process, this usually occurs at the cost of sub-retinal fibrosis and vision loss.
Traditional treatment of AMD relies on occlusion of the blood vessels using laser photocoagulation.
However, such treatment requires thermal destruction of the neovascular tissue, and is accompanied by full-thickness retinal damage, as well as damage to medium and large choroidal vessels. Further, the subject is left with an atrophic scar and visual scotoma.
DECREASE IN NEUROSENSORY RETINAL FUNCTION FOLLOWING
LASER THERAPY FOR CHOROIDAL NEOVASCULARIZATION
Background Of The Invention Loss of visual acuity is a common problem associated with aging and with various conditions of the eye. Particularly troublesome is the development of unwanted neovascularization in the cornea, retina or choroid. Choroidal neovascularization leads to hemorrhage and fibrosis, with resultant visual loss in a number of recognized eye diseases, including macular degeneration, ocular histoplasmosis syndrome, myopia, diabetic retinopathy and inflammatory diseases.
Age-related macular degeneration (AND) is the leading cause of new blindness in the elderly, and choroidal neovascularization is responsible for 800 of the severe visual loss in patients with this disease.
Although the natural history of the disease is eventual quiescence and regression of the neovascularization process, this usually occurs at the cost of sub-retinal fibrosis and vision loss.
Traditional treatment of AMD relies on occlusion of the blood vessels using laser photocoagulation.
However, such treatment requires thermal destruction of the neovascular tissue, and is accompanied by full-thickness retinal damage, as well as damage to medium and large choroidal vessels. Further, the subject is left with an atrophic scar and visual scotoma.
Moreover, recurrences are common, and visual prognosis is poor.
Recently, forms of photocoagulation have been devised which attempt to reduce the damage attendant to traditional photocoagulation. For example, transpupillary thermotherapy (TTT) utilizes a low intensity laser in combination with a large "spot"
(irradiation focal point) size and long exposure to close choroidal neovascularization and thereby treat macular degeneration. This procedure is said to reduce the amount of secondary damage seen in the use of traditional photocoagulation procedures.
Photodynamic Therapy Recent research in the treatment of neovascularization have had the aim of causing more selective closure of the blood vessels, in order to preserve the overlying neurosensory retina. One such strategy is a treatment termed photodynamic therapy or PDT, which relies on low intensity light exposure of photosensitized tissues to produce lesions in the newly developing blood vessels. In PDT, photoactive compounds are administered and allowed to reach a particular undesired tissue which is then irradiated with a light absorbed by the photoactive compound.
This results in destruction or impairment of the tissue immediately surrounding the locus of the photoactive compound without the more extensive ocular tissue damage seen when photocoagulation is used.
Recently, forms of photocoagulation have been devised which attempt to reduce the damage attendant to traditional photocoagulation. For example, transpupillary thermotherapy (TTT) utilizes a low intensity laser in combination with a large "spot"
(irradiation focal point) size and long exposure to close choroidal neovascularization and thereby treat macular degeneration. This procedure is said to reduce the amount of secondary damage seen in the use of traditional photocoagulation procedures.
Photodynamic Therapy Recent research in the treatment of neovascularization have had the aim of causing more selective closure of the blood vessels, in order to preserve the overlying neurosensory retina. One such strategy is a treatment termed photodynamic therapy or PDT, which relies on low intensity light exposure of photosensitized tissues to produce lesions in the newly developing blood vessels. In PDT, photoactive compounds are administered and allowed to reach a particular undesired tissue which is then irradiated with a light absorbed by the photoactive compound.
This results in destruction or impairment of the tissue immediately surrounding the locus of the photoactive compound without the more extensive ocular tissue damage seen when photocoagulation is used.
Photodynamic therapy of conditions in the eye has been attempted over the past several decades using various photoactive compounds, e.g., porphyrin derivatives, such as1hematoporphyrin derivative and Photofrin porfimer sodium; "green porphyrins", such as benzoporphyrin derivative (BPD), MA; and phthalocyanines. Photodynamic treatment of eye conditions has been reported to actually enhance the visual acuity of certain subjects in some circumstances. U.S. Patent No. 5,756,541.
However, although generally more safe than photocoagulation, there are certain dangers involved in performing PDT. For example, low intensity lasers in conjunction with the systemic injection of vertporfin is currently the only approved PDT for treatment of age-related macular degeneration. But studies have shown that the use of vertporfin at high doses (12 and 18 mg/mz) result in long term or permanent scarring of the retina, chronic absence of photoreceptor cells, and optic nerve atrophy. (Reinke et al., Ophthalmology 106:1915, October 1999). At lower concentrations of vertporfin (e.g., about 6 mg/m2) PDT is effective to slow vascular outgrowth and associated edema somewhat, but treatment appears to be necessary every few months.
Additionally, while PDT is clearly efficacious in some patients, this mode of treatment has resulted in a lower percentage of patients reporting an increase in visual acuity, or a halting in the progression of visual deterioration, than would be expected theoretically. The reasons for this have not been clearly understood in the literature, but may relate to PDT-induced neurosensory damage which limits efficacy.
The Alpha Adrenergic Receptors Human adrenergic receptors are integral membrane proteins which have been classified into two broad classes, the alpha and the beta adrenergic receptors.
Both types mediate the action of the peripheral sympathetic nervous system upon binding of catecholamines, norepinephrine and epinephrine.
Norepinephrine is produced by adrenergic nerve endings, while epinephrine is produced by the adrenal medulla. The binding affinity of adrenergic receptors for these compounds forms one basis of the classification: alpha receptors tend to bind norepinephrine more strongly than epinephrine and much more strongly than the synthetic compound isoproterenol. The preferred binding affinity of these hormones is reversed for the beta receptors. In many tissues, the functional responses, such as smooth muscle contraction, induced by alpha receptor activation are opposed to responses induced by beta receptor binding.
Subsequently, the functional distinction between alpha and beta receptors was further highlighted and refined by the pharmacological characterization of these receptors from various animal and tissue sources. As a result, alpha and beta adrenergic receptors were further subdivided into al, a2, h'1, and R2 subtypes.
Functional differences between a1 and a2 receptors have been recognized, and compounds which 5 exhibit selective binding between these two subtypes have been developed. Thus, in WO 92/0073, the selective ability of the R(+) enantiomer of terazosin to selectively bind to adrenergic receptors of the a1 subtype was reported. The a1/a2 selectivity of this compound was disclosed as being significant because agonist stimulation of the a2 receptors was said to inhibit secretion of epinephrine and norepinephrine, while antagonism of the a2 receptor was said to increase secretion of these hormones. Thus, the use of non-selective. alpha-adrenergic blockers, such as phenoxybenzamine and phentolamine, was said to be limited by their induction, through the a2 adrenergic receptors, of increased concentrations of plasma catecholamine and attendant physiological sequelae (increased heart rate and smooth muscle contraction).
For a general background on the a-adrenergic receptors', the reader's attention is directed to Robert R. Ruffolo, Jr., a-Adrenoreceptors: Molecular Biology, Biochemistry and Pharmacology, (Progress in Basic and Clinical Pharmacology series, Karger, 1991), in which the basis of al/a, subclassification, the molecular biology, signal transduction, agonist structure-activity relationships, receptor functions, and therapeutic applications for compounds exhibiting a-adrenergic receptor affinity is explored.
The cloning, sequencing and expression of alpha receptor subtypes from animal tissues has led to the subclassification of the a1 adrenoreceptors into the further classifications of a1A, a1B, and a1D. Similarly, the a2 adrenoreceptors have also been classified a2A, a2B, and a2C receptors. Each a2 receptor subtype appears to exhibit its own pharmacological and tissue specificities. Compounds having a degree of specificity for one or more of these subtypes may be more specific therapeutic agents for a given indication than the currently employed a2 receptor pan-agonists (such as the drugs clonidine and brimonidine) .
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1A shows that brimonidine inhibits the post PDT decrease in retinal functionality as compared to a saline control.
Figure 1B shows that brimonidine does not affect the area of ablation of CNV following PDT.
Figure 2B shows that Alphagari (brimonidine) has no effect on retinal thickness in non-PDT-treated rabbit eyes.
Figure 2B shows that brimonidine decreases the increase in retinal thickness (edema) appearing after PDT treatment.
However, although generally more safe than photocoagulation, there are certain dangers involved in performing PDT. For example, low intensity lasers in conjunction with the systemic injection of vertporfin is currently the only approved PDT for treatment of age-related macular degeneration. But studies have shown that the use of vertporfin at high doses (12 and 18 mg/mz) result in long term or permanent scarring of the retina, chronic absence of photoreceptor cells, and optic nerve atrophy. (Reinke et al., Ophthalmology 106:1915, October 1999). At lower concentrations of vertporfin (e.g., about 6 mg/m2) PDT is effective to slow vascular outgrowth and associated edema somewhat, but treatment appears to be necessary every few months.
Additionally, while PDT is clearly efficacious in some patients, this mode of treatment has resulted in a lower percentage of patients reporting an increase in visual acuity, or a halting in the progression of visual deterioration, than would be expected theoretically. The reasons for this have not been clearly understood in the literature, but may relate to PDT-induced neurosensory damage which limits efficacy.
The Alpha Adrenergic Receptors Human adrenergic receptors are integral membrane proteins which have been classified into two broad classes, the alpha and the beta adrenergic receptors.
Both types mediate the action of the peripheral sympathetic nervous system upon binding of catecholamines, norepinephrine and epinephrine.
Norepinephrine is produced by adrenergic nerve endings, while epinephrine is produced by the adrenal medulla. The binding affinity of adrenergic receptors for these compounds forms one basis of the classification: alpha receptors tend to bind norepinephrine more strongly than epinephrine and much more strongly than the synthetic compound isoproterenol. The preferred binding affinity of these hormones is reversed for the beta receptors. In many tissues, the functional responses, such as smooth muscle contraction, induced by alpha receptor activation are opposed to responses induced by beta receptor binding.
Subsequently, the functional distinction between alpha and beta receptors was further highlighted and refined by the pharmacological characterization of these receptors from various animal and tissue sources. As a result, alpha and beta adrenergic receptors were further subdivided into al, a2, h'1, and R2 subtypes.
Functional differences between a1 and a2 receptors have been recognized, and compounds which 5 exhibit selective binding between these two subtypes have been developed. Thus, in WO 92/0073, the selective ability of the R(+) enantiomer of terazosin to selectively bind to adrenergic receptors of the a1 subtype was reported. The a1/a2 selectivity of this compound was disclosed as being significant because agonist stimulation of the a2 receptors was said to inhibit secretion of epinephrine and norepinephrine, while antagonism of the a2 receptor was said to increase secretion of these hormones. Thus, the use of non-selective. alpha-adrenergic blockers, such as phenoxybenzamine and phentolamine, was said to be limited by their induction, through the a2 adrenergic receptors, of increased concentrations of plasma catecholamine and attendant physiological sequelae (increased heart rate and smooth muscle contraction).
For a general background on the a-adrenergic receptors', the reader's attention is directed to Robert R. Ruffolo, Jr., a-Adrenoreceptors: Molecular Biology, Biochemistry and Pharmacology, (Progress in Basic and Clinical Pharmacology series, Karger, 1991), in which the basis of al/a, subclassification, the molecular biology, signal transduction, agonist structure-activity relationships, receptor functions, and therapeutic applications for compounds exhibiting a-adrenergic receptor affinity is explored.
The cloning, sequencing and expression of alpha receptor subtypes from animal tissues has led to the subclassification of the a1 adrenoreceptors into the further classifications of a1A, a1B, and a1D. Similarly, the a2 adrenoreceptors have also been classified a2A, a2B, and a2C receptors. Each a2 receptor subtype appears to exhibit its own pharmacological and tissue specificities. Compounds having a degree of specificity for one or more of these subtypes may be more specific therapeutic agents for a given indication than the currently employed a2 receptor pan-agonists (such as the drugs clonidine and brimonidine) .
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1A shows that brimonidine inhibits the post PDT decrease in retinal functionality as compared to a saline control.
Figure 1B shows that brimonidine does not affect the area of ablation of CNV following PDT.
Figure 2B shows that Alphagari (brimonidine) has no effect on retinal thickness in non-PDT-treated rabbit eyes.
Figure 2B shows that brimonidine decreases the increase in retinal thickness (edema) appearing after PDT treatment.
SUMMARY OF THE INVENTION
The present invention concerns compositions and methods for the treatment of ocular neovascularization, including the reduction of neurosensory function, which is attendant to current therapies such as photocoagulation and PDT. In a preferred aspect, the invention is drawn to an improved method of performing photodynamic therapy comprising treating the patient with an effective amount of a neuroprotective agent, selected from alpha adrenergic receptor modulators. Preferably, the alpha adrenergic receptor modulator is an alpha adrenergic receptor agonist. In a further preferred embodiment, the alpha receptor agonist is an alpha 2 receptor agonist, even more preferably an alpha 2B and/or an alpha 2C agonist. It is preferred that these agents be at least selective, and even specific, for the indicated receptors or receptor subtypes.
The present invention is also directed to a method for reducing or eliminating a decrease in neurosensory retinal function following laser treatment of chorodial neovanscularization (CNV) while maintaining the vascular occlusion therapeutic effect of such therapy, the method comprising the steps: a) administering to a mammal having a CNV a therapeutically effective amount of an alpha receptor agonist, b) subjecting said mammal to laser irradiation of the retinal locus of the CNV; wherein the amount of neurosensory retinal function following steps a) and b) is greater than when said mammal is subjected to step b) without step a). In a preferred embodiment, the mammal is given a therapeutically effective amount of a pharmaceutically acceptable photoactivated dye capable of accumulation in the locus of a choroidal neovascularization and destroying tissue when exposed to light of the same wavelength as the laser.
The present invention concerns compositions and methods for the treatment of ocular neovascularization, including the reduction of neurosensory function, which is attendant to current therapies such as photocoagulation and PDT. In a preferred aspect, the invention is drawn to an improved method of performing photodynamic therapy comprising treating the patient with an effective amount of a neuroprotective agent, selected from alpha adrenergic receptor modulators. Preferably, the alpha adrenergic receptor modulator is an alpha adrenergic receptor agonist. In a further preferred embodiment, the alpha receptor agonist is an alpha 2 receptor agonist, even more preferably an alpha 2B and/or an alpha 2C agonist. It is preferred that these agents be at least selective, and even specific, for the indicated receptors or receptor subtypes.
The present invention is also directed to a method for reducing or eliminating a decrease in neurosensory retinal function following laser treatment of chorodial neovanscularization (CNV) while maintaining the vascular occlusion therapeutic effect of such therapy, the method comprising the steps: a) administering to a mammal having a CNV a therapeutically effective amount of an alpha receptor agonist, b) subjecting said mammal to laser irradiation of the retinal locus of the CNV; wherein the amount of neurosensory retinal function following steps a) and b) is greater than when said mammal is subjected to step b) without step a). In a preferred embodiment, the mammal is given a therapeutically effective amount of a pharmaceutically acceptable photoactivated dye capable of accumulation in the locus of a choroidal neovascularization and destroying tissue when exposed to light of the same wavelength as the laser.
In these methods, the alpha adrenergic receptor agonist is preferably an alpha 2 selective agonist, even more preferably an alpha 2B and/or alpha 2C
selective agonist, mthst preferably, an alpha 2B
selective agonist. In one preferred embodiment the alpha 2 selective agonist is selected from brimonidine, clonidine and para-aminoclonidine.
Other alpha 2B selective compounds include AGN
960, AGN 795 and AGN 923. The structure of AGN 960 is presented elsewhere in this patent application. The structure of AGN 795 is as follows:
N
NH
The structure of AGN 923 is as follows:
HN` \
N
By "effective amount" of a neuroprotective agent (such as an alpha adrenergic agonist) is meant an amount effective to reduce the amount of cell death among the neurons of the retina and optic nerve (e.g., photoreceptors, retinal ganglion cells, and bipolar cells, or any of these) caused by the photoactive 5 component of laser treatment as compared to a similarly situated CNV patient receiving laser treatment who does not receive treatment with the neuroprotective agent.
In another embodiment, the invention is drawn to 10 an improved method of performing photodynamic or photocoagulation therapy comprising treating the patient with an effective amount of an agent effective to protect the neurons of the retina and optic nerve (e.g., photoreceptors) from damage caused by laser irradiation or the photoactive component of PDT
treatment (neuroprotective agent).
An additional benefit of this therapy is the resultant reduction in edema and extravascularization of fluid that laser treatment causes. ' By "effective amount" of a neuroprotective agent is meant an amount of such agent effective to reduce the extent to which, or the rate at which, new blood vessels are formed in the retina of a CNV patient as compared to a similarly situated CNV patient not given the neuroprotective agent.
In a third embodiment, the invention is directed to an improved method of performing photodynamic therapy comprising treating the patient with an effective amount of a neuroprotective agent, and irradiating the CNV with laser light sufficient to directly or indirectly cause destruction of the CNV.
selective agonist, mthst preferably, an alpha 2B
selective agonist. In one preferred embodiment the alpha 2 selective agonist is selected from brimonidine, clonidine and para-aminoclonidine.
Other alpha 2B selective compounds include AGN
960, AGN 795 and AGN 923. The structure of AGN 960 is presented elsewhere in this patent application. The structure of AGN 795 is as follows:
N
NH
The structure of AGN 923 is as follows:
HN` \
N
By "effective amount" of a neuroprotective agent (such as an alpha adrenergic agonist) is meant an amount effective to reduce the amount of cell death among the neurons of the retina and optic nerve (e.g., photoreceptors, retinal ganglion cells, and bipolar cells, or any of these) caused by the photoactive 5 component of laser treatment as compared to a similarly situated CNV patient receiving laser treatment who does not receive treatment with the neuroprotective agent.
In another embodiment, the invention is drawn to 10 an improved method of performing photodynamic or photocoagulation therapy comprising treating the patient with an effective amount of an agent effective to protect the neurons of the retina and optic nerve (e.g., photoreceptors) from damage caused by laser irradiation or the photoactive component of PDT
treatment (neuroprotective agent).
An additional benefit of this therapy is the resultant reduction in edema and extravascularization of fluid that laser treatment causes. ' By "effective amount" of a neuroprotective agent is meant an amount of such agent effective to reduce the extent to which, or the rate at which, new blood vessels are formed in the retina of a CNV patient as compared to a similarly situated CNV patient not given the neuroprotective agent.
In a third embodiment, the invention is directed to an improved method of performing photodynamic therapy comprising treating the patient with an effective amount of a neuroprotective agent, and irradiating the CNV with laser light sufficient to directly or indirectly cause destruction of the CNV.
In another preferred aspect, the invention is drawn to an improved method of performing photodynamic therapy comprising treating the patient with an amount of a neuroprotective agent protect neural cells so as to thereby increase the amount of time necessary between PDT treatments and to slow the progression of ARMD and other ocular conditions in which neovascularization plays a part (for example ocular hiostoplasmosis syndrome (OHS) and pathogenic myopia) beyond that obtained by PDT or photocoagulation alone.
When an alpha adrenergic agonist or another agent having neuroprotective activity is used in conjunction with PDT or photocoagulation, it is preferred that the amount of such agent administered to the patient is an effective neuroprotective dose.
Determining the absolute dosage of the neuroprotective agent depends upon a number of factors, including the means of administration and delivery and the form of the drug. For intraocular delivery agent, such as by intravitreal or subretinal injection, dosages are preferably in the range of about 0.1 ug to about 100 ug per eye; more preferably in the range of about 0.20 ug to about 50 ug per eye;
even more preferably in the range of about 0.5 ug to about 10 ug per eye.
The neuroprotective agent may be delivered by any means effective to expose the retinal and optic nerve cells to the agent. Thus, such agents may be delivered systemically, such as by intravenous, intramuscular, or subcutaneous injection, or by oral delivery. Alternatively, the neuroprotective and/or neovascularization-inhibiting agent(s) may be delivered by direct injection into the eye, such as into the anterior chamber, posterior chamber or vitreous chamber, or by subretinal injection. The reagent may also be delivered topically to the ocular surface.
Another delivery method provides for sustained delivery of the noeuroprotective,agent using an intraocular implant. Such implants may be, for example, a biodegradable and/or biocompatible implant or insert such as the ocular implants and inserts disclosed in United States Patents No. 5,443,505, 5,824,072, 5,766,242; 4,853,224; 4,997,652; 5,164,188;
5,632,984; and 5,869,079. Such implants may be inserted into a chamber of the eye, such as the anterior, posterior or anterior chambers, or may be implanted in the sclera, transchoroidal space, or an avascularized region exterior to the vitreous.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is drawn to therapeutic methods and compositions for the treatment of intraocular neovascularization associated with conditions such as age-related macular degeneration (ARND), diabetic retinopathy, ocular histoplasmosis syndrome, and pathologic myopia.
The invention is more particularly concerned with therapeutic methods combining retinal photocoagulation or photodynamic therapy (PDT) with a neuroprotectant agent, preferably with an alpha adrenergic agonist.
In a preferred embodiment, the agent is an alpha 2 selective agonist; even more preferably an alpha 2B
and/or alpha 2C selective agonist. One can also combine the neuroprotective alpha adrenergic agonist with other neuroprotective agents to take advantage of different mechanistic means of providing neuroprotection.
In a preferred aspect of this embodiment of the invention, the neuroprotective agent is administered to the patient sufficiently prior to photcoagulation (such as TTT) or PDT treatment so as to be available to protect nerve cells upon the commencement of therapy. In another aspect of the invention, the alpha adrenergic receptor agonist is administered a sufficient time following photocoagulation or PDT
treatment to forestall nerve death due to such treatment.
Such methods are applicable to any photocoagulation method or to PDT treatment which makes use of any photoactive compound. Such photoactive compounds may include derivatives of hematoporphyrin, as described in U.S. Patents No.
5,028,621; 4,866,168; 4,649,151; and 5,438,071.
pheophorbides are described in U.S.Pat. Nos.
5,198,460; 5,002,962; and 5,093,349; bacteriochlorins in U.S. Pat. Nos. 5,171,741 and 5,173,504; dimers and trimers of hematoporphyrins in U.S. Pat. Nos, 4,968,715 and 5,190,966. Other possible photoactive compounds include purpurins, merocyanines and porphycenes. Of course, mixtures of photoactive compounds may be used in conjunction with each other.
A currently preferred photoactive compound is verteporf in (liposomal benzoporphyrin derivative).
This compound is currently the only photoactive agent approved by the U.S. Food and Drug Administration for treatment of choroidal neovascularization in conjunction with photodynamic therapy.
The photoactive agent is formulated so as to provide an effective concentration to the target ocular tissue. The photoactive agent may be coupled to a specific binding ligand which may bind to a specific surface component of the target ocular tissue, such as a cell surface receptor or, if desired, may be formulated with a carrier that delivers higher concentrations of the photoactive'agent to the target tissue. Exemplary ligands may be receptor antagonists or a variable region of an immunoglobulin molecule.
The nature of the formulation will depend in part on the mode of administration and on the nature of the photoactive agent selected. Any pharmaceutically acceptable excipient, or combination thereof, appropriate to and compatible with the particular photoactive compound may be used, Thus, the photoactive compound may be administered as an aqueous composition, as a transmucosal or transdermal, composition, or in an oral formulation. The formulation may also include liposomes. Liposomal compositions are particularly preferred especially where the photoactive agent is a green porphyrin.
Liposomal formulations are believed to deliver the green porphyrin with a measure of selectivity to the low-density lipoprotein component of plasma which, in 5 turn acts as a carrier to deliver the active ingredient more effectively to the desired site.
Increased numbers of LDL receptors have been shown to be associated with neovascularization, and by increasing the partitioning of the green porphyrin 10 into the lipoprotein phase of the blood, it appears to be delivered more efficiently to neovasculature.
Consistent with the chosen formulation, the photoactive compound may be delivered in a variety of ways. For example, delivery may be oral, peritoneal, 15 rectal, or topical (e.g., by installation directly into the eye). Alternatively, delivery may be by intravenous, intramuscular or subcutaneous injection.
The dosage of the photoactive compound may vary, according to the activity of the specific compound(s) chosen, the formulation, and whether the compound is joined to a carrier and thus targeted to a specific tissue as described above. When using green porphyrins, dosages are usually in the range of 0.1-50 mg/M2 of body surface area; more preferably from about 1-10 mg/M2 or from about 2-8 mg/M2 . Obviously, parameters to be considered when determining the dosage include the duration and wavelength of the light irradiation, the nature of the photochemical reaction induced by the light irradiation, and the dye-to-laser time period.
When an alpha adrenergic agonist or another agent having neuroprotective activity is used in conjunction with PDT or photocoagulation, it is preferred that the amount of such agent administered to the patient is an effective neuroprotective dose.
Determining the absolute dosage of the neuroprotective agent depends upon a number of factors, including the means of administration and delivery and the form of the drug. For intraocular delivery agent, such as by intravitreal or subretinal injection, dosages are preferably in the range of about 0.1 ug to about 100 ug per eye; more preferably in the range of about 0.20 ug to about 50 ug per eye;
even more preferably in the range of about 0.5 ug to about 10 ug per eye.
The neuroprotective agent may be delivered by any means effective to expose the retinal and optic nerve cells to the agent. Thus, such agents may be delivered systemically, such as by intravenous, intramuscular, or subcutaneous injection, or by oral delivery. Alternatively, the neuroprotective and/or neovascularization-inhibiting agent(s) may be delivered by direct injection into the eye, such as into the anterior chamber, posterior chamber or vitreous chamber, or by subretinal injection. The reagent may also be delivered topically to the ocular surface.
Another delivery method provides for sustained delivery of the noeuroprotective,agent using an intraocular implant. Such implants may be, for example, a biodegradable and/or biocompatible implant or insert such as the ocular implants and inserts disclosed in United States Patents No. 5,443,505, 5,824,072, 5,766,242; 4,853,224; 4,997,652; 5,164,188;
5,632,984; and 5,869,079. Such implants may be inserted into a chamber of the eye, such as the anterior, posterior or anterior chambers, or may be implanted in the sclera, transchoroidal space, or an avascularized region exterior to the vitreous.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is drawn to therapeutic methods and compositions for the treatment of intraocular neovascularization associated with conditions such as age-related macular degeneration (ARND), diabetic retinopathy, ocular histoplasmosis syndrome, and pathologic myopia.
The invention is more particularly concerned with therapeutic methods combining retinal photocoagulation or photodynamic therapy (PDT) with a neuroprotectant agent, preferably with an alpha adrenergic agonist.
In a preferred embodiment, the agent is an alpha 2 selective agonist; even more preferably an alpha 2B
and/or alpha 2C selective agonist. One can also combine the neuroprotective alpha adrenergic agonist with other neuroprotective agents to take advantage of different mechanistic means of providing neuroprotection.
In a preferred aspect of this embodiment of the invention, the neuroprotective agent is administered to the patient sufficiently prior to photcoagulation (such as TTT) or PDT treatment so as to be available to protect nerve cells upon the commencement of therapy. In another aspect of the invention, the alpha adrenergic receptor agonist is administered a sufficient time following photocoagulation or PDT
treatment to forestall nerve death due to such treatment.
Such methods are applicable to any photocoagulation method or to PDT treatment which makes use of any photoactive compound. Such photoactive compounds may include derivatives of hematoporphyrin, as described in U.S. Patents No.
5,028,621; 4,866,168; 4,649,151; and 5,438,071.
pheophorbides are described in U.S.Pat. Nos.
5,198,460; 5,002,962; and 5,093,349; bacteriochlorins in U.S. Pat. Nos. 5,171,741 and 5,173,504; dimers and trimers of hematoporphyrins in U.S. Pat. Nos, 4,968,715 and 5,190,966. Other possible photoactive compounds include purpurins, merocyanines and porphycenes. Of course, mixtures of photoactive compounds may be used in conjunction with each other.
A currently preferred photoactive compound is verteporf in (liposomal benzoporphyrin derivative).
This compound is currently the only photoactive agent approved by the U.S. Food and Drug Administration for treatment of choroidal neovascularization in conjunction with photodynamic therapy.
The photoactive agent is formulated so as to provide an effective concentration to the target ocular tissue. The photoactive agent may be coupled to a specific binding ligand which may bind to a specific surface component of the target ocular tissue, such as a cell surface receptor or, if desired, may be formulated with a carrier that delivers higher concentrations of the photoactive'agent to the target tissue. Exemplary ligands may be receptor antagonists or a variable region of an immunoglobulin molecule.
The nature of the formulation will depend in part on the mode of administration and on the nature of the photoactive agent selected. Any pharmaceutically acceptable excipient, or combination thereof, appropriate to and compatible with the particular photoactive compound may be used, Thus, the photoactive compound may be administered as an aqueous composition, as a transmucosal or transdermal, composition, or in an oral formulation. The formulation may also include liposomes. Liposomal compositions are particularly preferred especially where the photoactive agent is a green porphyrin.
Liposomal formulations are believed to deliver the green porphyrin with a measure of selectivity to the low-density lipoprotein component of plasma which, in 5 turn acts as a carrier to deliver the active ingredient more effectively to the desired site.
Increased numbers of LDL receptors have been shown to be associated with neovascularization, and by increasing the partitioning of the green porphyrin 10 into the lipoprotein phase of the blood, it appears to be delivered more efficiently to neovasculature.
Consistent with the chosen formulation, the photoactive compound may be delivered in a variety of ways. For example, delivery may be oral, peritoneal, 15 rectal, or topical (e.g., by installation directly into the eye). Alternatively, delivery may be by intravenous, intramuscular or subcutaneous injection.
The dosage of the photoactive compound may vary, according to the activity of the specific compound(s) chosen, the formulation, and whether the compound is joined to a carrier and thus targeted to a specific tissue as described above. When using green porphyrins, dosages are usually in the range of 0.1-50 mg/M2 of body surface area; more preferably from about 1-10 mg/M2 or from about 2-8 mg/M2 . Obviously, parameters to be considered when determining the dosage include the duration and wavelength of the light irradiation, the nature of the photochemical reaction induced by the light irradiation, and the dye-to-laser time period.
Light irradiation is performed a sufficient time after the administration of the photoactive compound so as to permit the compound to reach its target tissue. Upon being irradiated with the wavelength(s) appropriate to the compound(s) chosen, the compound enters an excited state and is thought to interact with other compounds to form highly reactive intermediates which can then destroy the target endothelial tissue, causing platelet aggregation and thrombosis. Fluence of the irradiation may vary depending on factors such as the depth of tissue to be treated and the tissue type - generally it is between about 25 and about 200 Joules/cm2. Irradiance typically is between about 150 and about 900 mW/cm2, but can also vary somewhat from this range.
Typically, light treatment is given about 5 minutes following administration of the photoactive drug. In a preferred embodiment, the photoactive drug is administered intravenously.
The other component(s) of the methods and composition of the present invention are a neuroprotective alpha adrenergic agent. Exemplary neuroprotective agents are, without exception, alpha 2 adrenergic pan-agonists such as brimonidine and clonidine, and alpha 2B and or alpha 2C selective agonists such as, without limitation, those mentioned in US Patent No. 6,313,172 and patent publications W00178703, W00178702,=W00100586 and W09928300.
Typically, light treatment is given about 5 minutes following administration of the photoactive drug. In a preferred embodiment, the photoactive drug is administered intravenously.
The other component(s) of the methods and composition of the present invention are a neuroprotective alpha adrenergic agent. Exemplary neuroprotective agents are, without exception, alpha 2 adrenergic pan-agonists such as brimonidine and clonidine, and alpha 2B and or alpha 2C selective agonists such as, without limitation, those mentioned in US Patent No. 6,313,172 and patent publications W00178703, W00178702,=W00100586 and W09928300.
In a preferred aspect of the invention a neuroprotective agent comprising an alpha adrenergic agonist is administered to the eye to protect it during and after PDT treatment. In an even more preferred embodiment of the invention, the neuroprotective agent is an alpha 2 selective agonist.
In a most preferred embodiment of the invention, the compound is an alpha 2B selective agonist.
Brimonidine has been reported to have neuroprotective activity. Hence, US Patent No.
5,856,329 and Yoles E., et al., Invest. Ophthalmol.
Vis. Sci. 40: 65 (1999)disclose this property of brimonidine; however, neither of these references makes any suggestion that brimonidine be used in the treatment of CNV.
The neuroprotective alpha adrenergic agent(s) of the present invention are delivered in any manner in which it is effective to protect neurons and/or inhibit neovascularization incident to photocoagulation or PDT treatment. Generally, the agent(s) is administered prior to laser treatment, so as to permit it to reach the ocular neural tissue before phototherapy. This will permit the agent(s) to have an immediate protective effect on neural cells.
However, the neovascularization-inhibiting benefits of such an agent can be realized even when given simultaneously with, or shortly after PDT treatment.
Additionally, the alpha adrenergic agents useful in the present method may be joined, in a manner similar to that of the photoactive compounds, to cell surface targeting ligands, such as portions of an antibody or immunologically active fragments to aid in targeting the drug to ocular cells, such as the optic nerve neurons and photoreceptors.
The neuroprotective alpha agonist agent may be formulated for oral delivery in, for example, a capsule, tablet or liquid, or for intravenous, intramuscular, or subcutaneous injection. In such a formulation, any suitable excipient may be added to such a formulation to stabilize the active ingredient and, particularly in the case of intravenous administration, to provide the necessary electrolyte balance. The alpha adrenergic agonists used in the methods of the present invention may also be formulated as a suppository or otherwise administered rectally. Formulations appropriate for rectal drug administration are well-known to those of skill in the art.
In yet another embodiment the alpha adrenergic agonist agents may be formulated within liposomes.
The liposomes are then able to fuse with a cell membrane, thus delivering the nucleic acid to receptors located at the cell surface and within the cell.
As indicated above, the neuroprotective agents to be used in the present invention may be administered by systemic delivery, as by intravenous, intramuscular or subcutaneous injection. In addition, these agents may be delivered directly to the eye by biocompatable and/or biodegradable implants or inserts (such as those described in patents cited and incorporated by reference above) containing the drug , or by direct injection into the eye, for example by intravitreal and/or subretinal injection. Alternatively, the alpha adrenergic agents may be topically applied to the surface in an drop.
The therapeutically effective dosage of such agents will depend upon factors including the mode of delivery, the specific activity of the polypeptide, and the formulation in which the agent is fabricated.
Once a formulation and route of administration is decided upon, determining a therapeutically effective dose is routine in the pharmaceutical arts, and can be readily determined without undue experimentation using suitable animal models such as, without limitation, non-human primates and rabbits.
Preferably, the dosage regimen of the neuroprotective agent will be such to permit the active aqent to remain in contact with retinal cells throughout the treatment period. Thus, the agent may be administered, for example, once or twice a day for 12 weeks.
Example 1 A 74 year old patient presents with "wet" age-related macular degeneration (ARMD) in the foveal region of the right eye, and his condition is found to be suitable for photodynamic therapy (PDT). For one week prior to the date of scheduled treatment, the patient is given a topical dosage of brimonidine twice a day in a standard formulation.
The day of scheduled PDT treatment, the patient is administered 6 mg/M2 of verteporfin. Fifteen 5 minutes after the start of the infusion, the patient is administered Irradiance of 600 mW/cm2 and total fluence of 50 Joules/cm2 from an Argon light laser.
Brimonidine administration is continued every two days throughout the 12 week evaluation period.
10 Evaluation of neural health is assayed 1 week, 4 weeks, and 12 weeks following treatment by visual inspection of the retina and test of visual acuity.
The affected areas of the retina appear healthy with no whitening (indicating lack of discernable retina 15 damage) or edema one week following PDT treatment;
this trend continues throughout the monitoring period.
Fluorescein angiography at same time points shows minimal leakage in the treated tissue after one week, and this minimal leakage continues throughout the 20 monitoring period. No evidence of renewed neovascularization can be seen 12 weeks following PDT
treatment. Additionally, no evidence of optic nerve axon loss can been seen. Tests of visual acuity 4 and 12 weeks following combined PDT and PEDF treatment show no discernable loss of vision, as a result of the treatment.
Example 2 Same facts as in Example 1, except that rather than being given topical brimonidine, the affected eye is given an biodegradable intraocular implant, by injection into the vitreous humor. The implant placed in the eye by intravitreal injection three days prior to PDT treatment ; and is readministered 10 days following PDT treatment. The retina is examined following the 12 week evaluation period.
Evaluation of neural health is assayed 1 week, 4 weeks, and 12 weeks following treatment by visual inspection of the retina and test of visual acuity.
The affected areas of the retina appear healthy with no whitening (indicating lack of discernable retina damage) one week following PDT treatment; this trend continues throughout the monitoring period.
Additionally, no evidence of optic nerve axon loss can been seen- Tests of visual acuity 4 and 12 weeks following combined PDT and PEDF treatment show no discernable loss of vision as a result of the treatment.
Example 3 Brown Norway rats weighing 200-400 grams were treated intraperitoneally (i.p.) with either brimonidine, AGN
960, or the saline vehicle. One hour later, the rats were unilaterally treated with PDT and evaluated by electroretinography 3-4 hours later. There were 4 rats in each treatment group.
PDT was conducted as follows: Mydriasis was induced in one eye of each rat with a drop of 0.5%
tropicamide. Rats were then anesthetized with isoflurane and placed on a platform in front of a slit lamp coupled to a Coherent diode laser for verteporfin TM
PDT (689 nm). Verteporf in was injected intravenously at a dose of 6 mg/m2. One minute later, the retina of one eye was irradiated with a 3 mm size spot at 50 J/cm2, 600 mW/cm2 in the superior hemisphere above the optic disk. Three to four hours later, the treated animals were again dilated and anesthetized, then electroretinograms (ERGs) were evaluated in each eye.
ERGs are collected non-invasively by measuring mass-cell response arising due to retinal activity proceeding from a light stimulus. The first cells stimulated by a flash light stimulation are the photoreceptors at the outer retinal layer. This response is measured as an a-wave. As the signal is transduced to inner retinal neurons, a b-wave is produced. The a-wave reflects activity in the photoreceptors and the b-wave reflects activity in both photoreceptors and bipolar cells.
Before being subjected to the ERG test, the rats were placed in the dark (dark-adapted) for 15 minutes.
Two types of ERG apparatus were used to generate the results below. In the initial brimonidine experiment, each eye was evaluated separately. A Grass photostimulator was placed 10 cm from the recording eye and flashed a single white flash lasting 10 microseconds. A gold corneal ring electrode with a reference electrode attached to the lower eyelid detected retinal responses. For the AGN 960 TM
experiments, a Ganzfeld dome was used to generate a single flash and sensitive bipolar corneal electrodes were placed on both eyes, thus allowing simultaneous ERGs to be done. A cushioning agent on the cornea (methylcellulose) was used in each case, and the responses were amplified and stored in a computer.
The results reported are a-wave amplitudes, which appear to be the ERG parameter most affected in clinical PDT. As can be seen below, the loss in retinal function induced by PDT was inhibited by an alpha-2 receptor pan agonist (brimonidine)and a selective alpha-2B receptor agonist (AGN 960).
AGN 960 has the following structure:
H
f NS
CNH
/~ Brimonidine has the following structure:
N N
N N N
H
Br A Wave Amplitude (uV) Agent Dose N PDT Eye Control % Control Eye Vehicle 1 ml/kg 4 70 18 104 17 67 12 Brimonidine 1000 4 90 15 91 21 103 8 ug/kg Vehicle 1 ml/kg 4 120 12 228 17 53 3 ug/kg Table 1. A-wave reflects photoreceptor function. Animals were treated with the indicated agent or vehicle i.p. 1 hour prior to PDT. * = p <_ 0.05, comparison between drug and vehicle-treated animals utilizing an unpaired Student's t-test Example 4 Seven pigmented rabbits were dosed with either 0.5 mis of 0.2% brimonidine (alphagan) or saline administered retrobulbarly in 1 eye of each rabbit.
One hour later, the animals were treated with a 10 minute intravenous infusion of 0.2 mg/kg verteporfin, then the same eye was irradiated 10 minutes later in the lower fundus with a 689 nm diode laser at 50 J/cm2, 600 mW/cm2 and a spot size of 1.5 mm.
Treated eyes were then imaged by ocular coherence tomography; this method gives a measure of retinal thickness at the following time points after PDT
(hours): 4, 24, 48, 72. Data are presented in Figure 1A and 1B; and show that brimonidine reduced the increase in retinal thickness (subretinal cyst +
retina) in the lesion produced by PDT.
These examples illustrate certain embodiments of the present invention; however, it will be understood that the invention is solely defined by the claims that conclude this specification.
In a most preferred embodiment of the invention, the compound is an alpha 2B selective agonist.
Brimonidine has been reported to have neuroprotective activity. Hence, US Patent No.
5,856,329 and Yoles E., et al., Invest. Ophthalmol.
Vis. Sci. 40: 65 (1999)disclose this property of brimonidine; however, neither of these references makes any suggestion that brimonidine be used in the treatment of CNV.
The neuroprotective alpha adrenergic agent(s) of the present invention are delivered in any manner in which it is effective to protect neurons and/or inhibit neovascularization incident to photocoagulation or PDT treatment. Generally, the agent(s) is administered prior to laser treatment, so as to permit it to reach the ocular neural tissue before phototherapy. This will permit the agent(s) to have an immediate protective effect on neural cells.
However, the neovascularization-inhibiting benefits of such an agent can be realized even when given simultaneously with, or shortly after PDT treatment.
Additionally, the alpha adrenergic agents useful in the present method may be joined, in a manner similar to that of the photoactive compounds, to cell surface targeting ligands, such as portions of an antibody or immunologically active fragments to aid in targeting the drug to ocular cells, such as the optic nerve neurons and photoreceptors.
The neuroprotective alpha agonist agent may be formulated for oral delivery in, for example, a capsule, tablet or liquid, or for intravenous, intramuscular, or subcutaneous injection. In such a formulation, any suitable excipient may be added to such a formulation to stabilize the active ingredient and, particularly in the case of intravenous administration, to provide the necessary electrolyte balance. The alpha adrenergic agonists used in the methods of the present invention may also be formulated as a suppository or otherwise administered rectally. Formulations appropriate for rectal drug administration are well-known to those of skill in the art.
In yet another embodiment the alpha adrenergic agonist agents may be formulated within liposomes.
The liposomes are then able to fuse with a cell membrane, thus delivering the nucleic acid to receptors located at the cell surface and within the cell.
As indicated above, the neuroprotective agents to be used in the present invention may be administered by systemic delivery, as by intravenous, intramuscular or subcutaneous injection. In addition, these agents may be delivered directly to the eye by biocompatable and/or biodegradable implants or inserts (such as those described in patents cited and incorporated by reference above) containing the drug , or by direct injection into the eye, for example by intravitreal and/or subretinal injection. Alternatively, the alpha adrenergic agents may be topically applied to the surface in an drop.
The therapeutically effective dosage of such agents will depend upon factors including the mode of delivery, the specific activity of the polypeptide, and the formulation in which the agent is fabricated.
Once a formulation and route of administration is decided upon, determining a therapeutically effective dose is routine in the pharmaceutical arts, and can be readily determined without undue experimentation using suitable animal models such as, without limitation, non-human primates and rabbits.
Preferably, the dosage regimen of the neuroprotective agent will be such to permit the active aqent to remain in contact with retinal cells throughout the treatment period. Thus, the agent may be administered, for example, once or twice a day for 12 weeks.
Example 1 A 74 year old patient presents with "wet" age-related macular degeneration (ARMD) in the foveal region of the right eye, and his condition is found to be suitable for photodynamic therapy (PDT). For one week prior to the date of scheduled treatment, the patient is given a topical dosage of brimonidine twice a day in a standard formulation.
The day of scheduled PDT treatment, the patient is administered 6 mg/M2 of verteporfin. Fifteen 5 minutes after the start of the infusion, the patient is administered Irradiance of 600 mW/cm2 and total fluence of 50 Joules/cm2 from an Argon light laser.
Brimonidine administration is continued every two days throughout the 12 week evaluation period.
10 Evaluation of neural health is assayed 1 week, 4 weeks, and 12 weeks following treatment by visual inspection of the retina and test of visual acuity.
The affected areas of the retina appear healthy with no whitening (indicating lack of discernable retina 15 damage) or edema one week following PDT treatment;
this trend continues throughout the monitoring period.
Fluorescein angiography at same time points shows minimal leakage in the treated tissue after one week, and this minimal leakage continues throughout the 20 monitoring period. No evidence of renewed neovascularization can be seen 12 weeks following PDT
treatment. Additionally, no evidence of optic nerve axon loss can been seen. Tests of visual acuity 4 and 12 weeks following combined PDT and PEDF treatment show no discernable loss of vision, as a result of the treatment.
Example 2 Same facts as in Example 1, except that rather than being given topical brimonidine, the affected eye is given an biodegradable intraocular implant, by injection into the vitreous humor. The implant placed in the eye by intravitreal injection three days prior to PDT treatment ; and is readministered 10 days following PDT treatment. The retina is examined following the 12 week evaluation period.
Evaluation of neural health is assayed 1 week, 4 weeks, and 12 weeks following treatment by visual inspection of the retina and test of visual acuity.
The affected areas of the retina appear healthy with no whitening (indicating lack of discernable retina damage) one week following PDT treatment; this trend continues throughout the monitoring period.
Additionally, no evidence of optic nerve axon loss can been seen- Tests of visual acuity 4 and 12 weeks following combined PDT and PEDF treatment show no discernable loss of vision as a result of the treatment.
Example 3 Brown Norway rats weighing 200-400 grams were treated intraperitoneally (i.p.) with either brimonidine, AGN
960, or the saline vehicle. One hour later, the rats were unilaterally treated with PDT and evaluated by electroretinography 3-4 hours later. There were 4 rats in each treatment group.
PDT was conducted as follows: Mydriasis was induced in one eye of each rat with a drop of 0.5%
tropicamide. Rats were then anesthetized with isoflurane and placed on a platform in front of a slit lamp coupled to a Coherent diode laser for verteporfin TM
PDT (689 nm). Verteporf in was injected intravenously at a dose of 6 mg/m2. One minute later, the retina of one eye was irradiated with a 3 mm size spot at 50 J/cm2, 600 mW/cm2 in the superior hemisphere above the optic disk. Three to four hours later, the treated animals were again dilated and anesthetized, then electroretinograms (ERGs) were evaluated in each eye.
ERGs are collected non-invasively by measuring mass-cell response arising due to retinal activity proceeding from a light stimulus. The first cells stimulated by a flash light stimulation are the photoreceptors at the outer retinal layer. This response is measured as an a-wave. As the signal is transduced to inner retinal neurons, a b-wave is produced. The a-wave reflects activity in the photoreceptors and the b-wave reflects activity in both photoreceptors and bipolar cells.
Before being subjected to the ERG test, the rats were placed in the dark (dark-adapted) for 15 minutes.
Two types of ERG apparatus were used to generate the results below. In the initial brimonidine experiment, each eye was evaluated separately. A Grass photostimulator was placed 10 cm from the recording eye and flashed a single white flash lasting 10 microseconds. A gold corneal ring electrode with a reference electrode attached to the lower eyelid detected retinal responses. For the AGN 960 TM
experiments, a Ganzfeld dome was used to generate a single flash and sensitive bipolar corneal electrodes were placed on both eyes, thus allowing simultaneous ERGs to be done. A cushioning agent on the cornea (methylcellulose) was used in each case, and the responses were amplified and stored in a computer.
The results reported are a-wave amplitudes, which appear to be the ERG parameter most affected in clinical PDT. As can be seen below, the loss in retinal function induced by PDT was inhibited by an alpha-2 receptor pan agonist (brimonidine)and a selective alpha-2B receptor agonist (AGN 960).
AGN 960 has the following structure:
H
f NS
CNH
/~ Brimonidine has the following structure:
N N
N N N
H
Br A Wave Amplitude (uV) Agent Dose N PDT Eye Control % Control Eye Vehicle 1 ml/kg 4 70 18 104 17 67 12 Brimonidine 1000 4 90 15 91 21 103 8 ug/kg Vehicle 1 ml/kg 4 120 12 228 17 53 3 ug/kg Table 1. A-wave reflects photoreceptor function. Animals were treated with the indicated agent or vehicle i.p. 1 hour prior to PDT. * = p <_ 0.05, comparison between drug and vehicle-treated animals utilizing an unpaired Student's t-test Example 4 Seven pigmented rabbits were dosed with either 0.5 mis of 0.2% brimonidine (alphagan) or saline administered retrobulbarly in 1 eye of each rabbit.
One hour later, the animals were treated with a 10 minute intravenous infusion of 0.2 mg/kg verteporfin, then the same eye was irradiated 10 minutes later in the lower fundus with a 689 nm diode laser at 50 J/cm2, 600 mW/cm2 and a spot size of 1.5 mm.
Treated eyes were then imaged by ocular coherence tomography; this method gives a measure of retinal thickness at the following time points after PDT
(hours): 4, 24, 48, 72. Data are presented in Figure 1A and 1B; and show that brimonidine reduced the increase in retinal thickness (subretinal cyst +
retina) in the lesion produced by PDT.
These examples illustrate certain embodiments of the present invention; however, it will be understood that the invention is solely defined by the claims that conclude this specification.
Claims (20)
1. Use of an alpha receptor agonist for the manufacture of a medicament for use in reducing or eliminating a decrease in neurosensory retinal function in a mammal following laser treatment of choroidal neovascularization (CNV) while maintaining the vascular occlusion therapeutic effect of the treatment, wherein the alpha receptor agonist is selected from the group consisting of an alpha-2B selective agonist, an alpha-2C
selective agonist, clonidine, and para-aminoclonidine, and wherein the amount of neurosensory retinal function following the use of the medicament and the laser treatment is greater than when said mammal is subjected to the laser treatment without use of the medicament.
selective agonist, clonidine, and para-aminoclonidine, and wherein the amount of neurosensory retinal function following the use of the medicament and the laser treatment is greater than when said mammal is subjected to the laser treatment without use of the medicament.
2. The use of claim 1, wherein the medicament is for combined use with a photoactive agent such that both the medicament and the photoactive agent are present in the CNV during laser treatment of CNV.
3. Use of a neuroprotectant compound for the manufacture of a medicament for use in protecting ocular neural tissue from damage caused by electromagnetic irradiation of the retina wherein the compound is for delivery to a patient's ocular neural tissue in an amount of said neuroprotectant compound effective to protect a plurality of ocular neurons from cell death as compared to ocular neuron cell death following the electromagnetic irradiation observed in the absence of said neuroprotectant compound, wherein said neuroprotectant is selected from the group consisting of an alpha-2B selective agonist, an alpha-2C
selective agonist, clonidine, and para-aminoclonidine.
selective agonist, clonidine, and para-aminoclonidine.
4. The use of claim 3, wherein said electromagnetic irradiation is laser irradiation.
5. The use of claim 1 or 3, wherein said alpha-2B selective agonist is selected from the group consisting of AGN 960, AGN
795, and AGN-923.
795, and AGN-923.
6. The use of claim 5, wherein the alpha-2B selective agonist is AGN 960.
7. The use of claim 5, wherein the alpha-2B selective agonist is AGN 795.
8. The use of claim 5, wherein the alpha-2B selective agonist is AGN 923.
9. The use of claim 3, wherein said neuroprotectant compound is for localization within ocular tissue prior to said electromagnetic irradiation.
10. The use of claim 3, wherein said neuroprotectant compound is for use following said electromagnetic irradiation.
11. Use of an alpha receptor agonist for reducing or eliminating a decrease in neurosensory retinal function in a mammal following laser treatment of choroidal neovascularization (CNV) while maintaining the vascular occlusion therapeutic effect of the treatment, wherein the alpha receptor agonist is selected from the group consisting of an alpha-2B selective agonist, an alpha-2C
selective agonist, clonidine, and para-aminoclonidine, and wherein the amount of neurosensory retinal function following the use of the alpha receptor agonist and the laser treament is greater than when said mammal is subjected to the laser treatment without use of the alpha receptor agonist.
selective agonist, clonidine, and para-aminoclonidine, and wherein the amount of neurosensory retinal function following the use of the alpha receptor agonist and the laser treament is greater than when said mammal is subjected to the laser treatment without use of the alpha receptor agonist.
12. The use of claim 1, wherein the alpha receptor agonist is for combined use with a photoactive agent such that both the alpha receptor agonist and the photoactive agent are present in the CNV during laser treatment of CNV.
13. Use of a neuroprotectant for protecting ocular neural tissue from damage caused by electromagnetic irradiation of the retina wherein the compound is for delivery to a patient's ocular neural tissue in an amount of said neuroprotectant compound effective to protect a plurality of ocular neurons from cell death as compared to ocular neuron cell death following the electromagnetic irradiation observed in the absence of said neuroprotectant compound, wherein said neuroprotectant is selected from the group consisting of an alpha-2B selective agonist, an alpha-2C
selective agonist, clonidine, and para-aminoclonidine.
selective agonist, clonidine, and para-aminoclonidine.
14. The use of claim 13, wherein said electromagnetic irradiation is laser irradiation.
15. The use of claim 11 or 13, wherein said alpha-2B selective agonist is selected from the group consisting of AGN 960, AGN
795, and AGN-923.
795, and AGN-923.
16. The use of claim 15, wherein the alpha-2B selective agonist is AGN 960.
17. The use of claim 15, wherein the alpha-2B selective agonist is AGN 795.
18. The use of claim 15, wherein the alpha-2B selective agonist is AGN 923.
19. The use of claim 13, wherein said neuroprotectant compound is for localization within ocular tissue prior to said electromagnetic irradiation.
20. The use of claim 13, wherein said neuroprotectant compound is for use following said electromagnetic irradiation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24485000P | 2000-11-01 | 2000-11-01 | |
| US60/244,850 | 2000-11-01 | ||
| PCT/US2001/046014 WO2002036162A2 (en) | 2000-11-01 | 2001-11-01 | Compositions for treatment of ocular neovascularization and neural injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2427655A1 CA2427655A1 (en) | 2002-05-10 |
| CA2427655C true CA2427655C (en) | 2011-07-26 |
Family
ID=22924381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2427655A Expired - Fee Related CA2427655C (en) | 2000-11-01 | 2001-11-01 | Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20020094998A1 (en) |
| EP (1) | EP1353692B1 (en) |
| JP (1) | JP4198988B2 (en) |
| AT (1) | ATE426413T1 (en) |
| AU (3) | AU2002248284A1 (en) |
| CA (1) | CA2427655C (en) |
| DE (1) | DE60138137D1 (en) |
| ES (1) | ES2322030T3 (en) |
| HK (1) | HK1059037A1 (en) |
| WO (2) | WO2002058730A2 (en) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080138294A1 (en) * | 1999-07-16 | 2008-06-12 | Igor Gonda | Systems and methods for effecting cessation of tobacco use |
| US20080138399A1 (en) * | 1999-07-16 | 2008-06-12 | Aradigm Corporation | Dual release nicotine formulations, and systems and methods for their use |
| US8256433B2 (en) * | 1999-07-16 | 2012-09-04 | Aradigm Corporation | Systems and methods for effecting cessation of tobacco use |
| US20080138398A1 (en) * | 1999-07-16 | 2008-06-12 | Aradigm Corporation | Dual release nicotine formulations, and systems and methods for their use |
| US20030082183A1 (en) * | 2000-11-01 | 2003-05-01 | Wheeler Larry A. | Methods and compositions for treatment of ocular neovascularization and neural injury |
| US7753943B2 (en) * | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
| US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7323485B2 (en) | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7276522B2 (en) | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7358269B2 (en) | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
| US20040138312A1 (en) * | 2002-10-08 | 2004-07-15 | Wheeler Larry A. | Methods for the treatment of neurodegeneration |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| CA2504024A1 (en) * | 2002-10-31 | 2004-05-21 | Celgene Corporation | Composition for the treatment of macular degeneration |
| ATE442861T1 (en) * | 2003-03-07 | 2009-10-15 | Univ Texas | PHOTODYNAMIC THERAPY DIRECTED AGAINST ANTIBODIES |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070224278A1 (en) * | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| BRPI0506983A (en) | 2004-01-20 | 2007-07-03 | Allergan Inc | localized eye therapy compositions, preferably comprising triamcinolone acetonide and hyaluronic acid |
| US7992570B2 (en) * | 2004-04-22 | 2011-08-09 | Light Sciences Oncology, Inc. | Fractionated light PDT therapy for posterior eye disease |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US8147865B2 (en) * | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8512738B2 (en) | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
| US8529927B2 (en) | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US20080033053A1 (en) * | 2004-07-22 | 2008-02-07 | Wolfgang Curt D | Cross-Reference To Related Applications |
| WO2006036497A2 (en) | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| BRPI0516025A (en) | 2004-09-24 | 2008-08-19 | Allergan Sales Inc | 4- (heteroaryl-methyl and substituted heteroaryl-methyl) -imidazol-2-thione acting as alpha2-adrenergic agonists |
| NZ553341A (en) | 2004-09-24 | 2010-11-26 | Allergan Inc | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
| CA2582071A1 (en) * | 2004-09-28 | 2006-04-06 | Allergan, Inc. | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same |
| US20060110429A1 (en) * | 2004-11-24 | 2006-05-25 | Therakine Corporation | Implant for intraocular drug delivery |
| US20060223750A1 (en) * | 2005-04-01 | 2006-10-05 | Allergan, Inc. | Agents and methods for enhancing photodynamic therapy |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| EP2119439A3 (en) * | 2005-05-17 | 2010-01-27 | Santen Pharmaceutical Co., Ltd. | Angiogenesis inhibitor for treating macular degeneration |
| US20070167527A1 (en) * | 2006-01-13 | 2007-07-19 | Burke James A | Memantine for the normalization of visual acuity deficits |
| ES2329636B2 (en) | 2006-02-17 | 2010-07-26 | Universitat De Valencia, Estudi General (Participa Con El 70%) | USE OF PEDF FACTOR TO INDUCE MOTHER CELLS SELF-RENEWAL |
| US8536445B2 (en) * | 2006-06-02 | 2013-09-17 | Emcore Solar Power, Inc. | Inverted metamorphic multijunction solar cells |
| US20080102097A1 (en) * | 2006-10-31 | 2008-05-01 | Zanella John M | Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
| US8470360B2 (en) | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
| US9072727B2 (en) | 2008-04-18 | 2015-07-07 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of degenerative disc disease |
| US20090264477A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc., An Indiana Corporation | Beta adrenergic receptor agonists for treatment of pain and/or inflammation |
| US20090263489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation |
| US8956641B2 (en) * | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of inflammatory diseases |
| US8946277B2 (en) * | 2008-04-18 | 2015-02-03 | Warsaw Orthopedic, Inc. | Clonidine formulations in a biodegradable polymer carrier |
| US9610243B2 (en) | 2008-04-18 | 2017-04-04 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
| USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
| US8420114B2 (en) * | 2008-04-18 | 2013-04-16 | Warsaw Orthopedic, Inc. | Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation |
| US9132085B2 (en) | 2008-04-18 | 2015-09-15 | Warsaw Orthopedic, Inc. | Compositions and methods for treating post-operative pain using clonidine and bupivacaine |
| US8557273B2 (en) | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
| US8629172B2 (en) | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
| US8883768B2 (en) | 2008-04-18 | 2014-11-11 | Warsaw Orthopedic, Inc. | Fluocinolone implants to protect against undesirable bone and cartilage destruction |
| US9132119B2 (en) * | 2008-04-18 | 2015-09-15 | Medtronic, Inc. | Clonidine formulation in a polyorthoester carrier |
| US20090264489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation |
| US20090263451A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain |
| US8722079B2 (en) | 2008-04-18 | 2014-05-13 | Warsaw Orthopedic, Inc. | Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine |
| GB0811955D0 (en) | 2008-06-30 | 2008-07-30 | Pci Biotech As | Method |
| US20100098746A1 (en) * | 2008-10-20 | 2010-04-22 | Warsaw Orthopedic, Inc. | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US8822546B2 (en) * | 2008-12-01 | 2014-09-02 | Medtronic, Inc. | Flowable pharmaceutical depot |
| US20100228097A1 (en) * | 2009-03-04 | 2010-09-09 | Warsaw Orthopedic, Inc. | Methods and compositions to diagnose pain |
| US20100239632A1 (en) * | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
| US8617583B2 (en) * | 2009-07-17 | 2013-12-31 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis |
| US8231891B2 (en) * | 2009-07-31 | 2012-07-31 | Warsaw Orthopedic, Inc. | Implantable drug depot for weight control |
| US20110111008A1 (en) * | 2009-10-08 | 2011-05-12 | Weng Tao | Use of PEDF in an Encapsulated Cell-Based Delivery System |
| US20110097375A1 (en) | 2009-10-26 | 2011-04-28 | Warsaw Orthopedic, Inc. | Formulation for preventing or reducing bleeding at a surgical site |
| EP2498783B1 (en) | 2009-11-09 | 2018-08-22 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| AU2011207281B2 (en) | 2010-01-22 | 2016-10-20 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| US20110182831A1 (en) * | 2010-01-25 | 2011-07-28 | Aradigm Corporation | Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use |
| PT2605771T (en) | 2010-08-16 | 2018-07-09 | Allergan Inc | Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists |
| US20130046003A1 (en) * | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| CA2901280A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US5958875A (en) * | 1996-03-29 | 1999-09-28 | The Regents Of The University Of California | Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity |
| US6100254A (en) * | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| ES2311507T3 (en) * | 2000-02-10 | 2009-02-16 | MASSACHUSETTS EYE & EAR INFIRMARY | PHOTODYNAMIC THERAPY FOR TREATMENT OF OPHTHALMIC AFFECTIONS. |
| UA75350C2 (en) * | 2000-03-24 | 2006-04-17 | Novartis Ag | Method for photodynamic treatment of undesirable subfoveal choroidal neovascularization using antiangiogenic agent |
| US8106038B2 (en) * | 2001-02-15 | 2012-01-31 | Qlt Inc. | Method for reducing or preventing PDT related inflammation |
-
2001
- 2001-10-26 AU AU2002248284A patent/AU2002248284A1/en not_active Abandoned
- 2001-10-26 WO PCT/US2001/051062 patent/WO2002058730A2/en active Application Filing
- 2001-11-01 AU AU2002230567A patent/AU2002230567B2/en not_active Ceased
- 2001-11-01 AU AU3056702A patent/AU3056702A/en active Pending
- 2001-11-01 DE DE60138137T patent/DE60138137D1/en not_active Expired - Lifetime
- 2001-11-01 JP JP2002538971A patent/JP4198988B2/en not_active Expired - Lifetime
- 2001-11-01 EP EP01990804A patent/EP1353692B1/en not_active Expired - Lifetime
- 2001-11-01 CA CA2427655A patent/CA2427655C/en not_active Expired - Fee Related
- 2001-11-01 WO PCT/US2001/046014 patent/WO2002036162A2/en active Application Filing
- 2001-11-01 ES ES01990804T patent/ES2322030T3/en not_active Expired - Lifetime
- 2001-11-01 AT AT01990804T patent/ATE426413T1/en not_active IP Right Cessation
- 2001-11-01 US US09/998,718 patent/US20020094998A1/en not_active Abandoned
-
2004
- 2004-03-15 HK HK04101890.5A patent/HK1059037A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60138137D1 (en) | 2009-05-07 |
| EP1353692B1 (en) | 2009-03-25 |
| CA2427655A1 (en) | 2002-05-10 |
| US20020094998A1 (en) | 2002-07-18 |
| JP2004512378A (en) | 2004-04-22 |
| ATE426413T1 (en) | 2009-04-15 |
| AU3056702A (en) | 2002-05-15 |
| HK1059037A1 (en) | 2004-06-18 |
| WO2002036162A2 (en) | 2002-05-10 |
| JP4198988B2 (en) | 2008-12-17 |
| AU2002248284A1 (en) | 2002-08-06 |
| ES2322030T3 (en) | 2009-06-16 |
| EP1353692A2 (en) | 2003-10-22 |
| WO2002036162A3 (en) | 2003-08-21 |
| WO2002058730A2 (en) | 2002-08-01 |
| AU2002230567B2 (en) | 2007-01-18 |
| WO2002058730A3 (en) | 2003-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2427655C (en) | Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization | |
| AU2002230567A1 (en) | Compositions for treatment of ocular neovascularization and neural injury | |
| TWI260327B (en) | Pharmaceutical compositions for treating ocular neovascular diseases | |
| Brown et al. | ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery | |
| Kramer et al. | Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys | |
| US20060293270A1 (en) | Methods and compositions for treating ocular disorders | |
| JP4975440B2 (en) | Improvement of macular degeneration and other ophthalmic diseases | |
| US20070027102A1 (en) | Methods and compositions for treating macular degeneration | |
| PL188888B1 (en) | Method of improving the power of vision through photodynamic therapy of an eye | |
| US6524330B1 (en) | Method of ocular treatment | |
| CA2474154A1 (en) | Methods for treating eye disorders | |
| US20060229284A1 (en) | Enhanced occlusive effect photodynamic therapy | |
| Matsubara et al. | Investigating the effect of ciliary body photodynamic therapy in a glaucoma mouse model | |
| Husain et al. | Photodynamic therapy of exudative age-related macular degeneration | |
| AU2006201701B2 (en) | Methods and compositions for treatment of ocular neovascularization and neural injury | |
| Favilla et al. | Phototherapy of posterior uveal melanomas. | |
| WO2006107598A2 (en) | Conjugates of photoactive compound and a bulking group for enhancing photodynamic therapy | |
| RU2198641C2 (en) | Method for treating ophthalmic diseases | |
| RU2192828C2 (en) | Method for treating the cases of proliferating diabetic retinopathy | |
| WO2005018634A1 (en) | The use of the hernatoporphyrin monomethyl ether for the treatment of the eye disorders | |
| AU2002363336A1 (en) | Methods for treating ocular neovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20161101 |